- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
Dr Jabbour discussed recent phase 3 PhALLCON trial (NCT03589326) data, supporting more potent third-generation tyrosine kinase inhibitor (TKI) ponatinib’s move to the frontline for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Adding ponatinib up front doubled minimal residual disease negativity complete response rates vs standard second-generation TKIs, meeting the primary end point. More patients avoided transplant, with improved event-free survival. Manageable cardiovascular risk was shown with dose adjustment. Dr McCloskey addressed challenges in Ph+ ALL and said selecting optimal TKI therapy is still based on patient factors, but ponatinib’s early activity and favorable safety support its use earlier in therapy to improve outcomes.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
